BioInvent continues to validate its pipeline with a trio of scientific updates. At ASH, the company presented deep responses for the BI-1206 triple combination in Non-Hodgkin’s lymphoma alongside strong activity for BI-1808 in cutaneous T-cell lymphoma. The latter poster received the “Abstract Achievement Award”. In parallel, a new publication in Clinical Cancer Research reinforces the FcγRIIB-blocking platform. To learn more, BioStock turned to CEO Martin Welschof for a comment.

Read the full interview at biostock.se:

BioInvent delivers double success at ASH and validates platform

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter
Follow BioStock on social media: LinkedIn and Facebook!  

About BioStock
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Läs mer på BioStock

Ämnen i artikeln

BioInvent International

Senast

28,90

1 dag %

0,87%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån